Session Organizers: John Osborn, University of Minnesota and Ziad Nahas, University of Minnesota
Effect of chronic cervical vagal nerve stimulation on systems physiology in humans: The REVEAL study
John Osborn, PhD
Professor and Director of the Minnesota Consortium for Autonomic Neuromodulation
University of Minnesota
Dr. Osborn’s research efforts are concentrated on therapies for the treatment of cardiovascular and metabolic diseases. He has made important contributions to our understanding the role of the sympathetic nervous system in the pathogenesis of hypertension. Dr. Osborn is also an internationally recognized expert in the development of autonomic neuromodulation therapies.
RESET-RA: Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
Amy Derosier
Vice President, Clinical Affairs
SetPoint Medical
Currently, Amy is Vice President of Clinical Affairs at SetPoint Medical, an early-stage MedTech company developing a novel platform to stimulate the vagus nerve for treating inflammatory, autoimmune diseases like rheumatoid arthritis (RESET-RA, primary analysis completed) and multiple sclerosis (pilot study). Amy attended the University of Minnesota and holds a Bachelor of Science in Nursing and has overseen multiple clinical evaluations for novel medical devices.
Vagus Nerve Stimulation for treatment-resistant depression: The RECOVER study
Ziad Nahas, MD, MSCR
Executive Vice Chair, Professor
University of Minnesota
My scientific interests lie in translational research of mood dysregulation and depressive disorders. My unique expertise is in functional neuroimaging and brain stimulation across various modalities [Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS), Prefrontal Cortical Stimulation (PCS), Deep Brain Stimulation (DBS), Electroconvulsive Therapy (ECT) and Focally Electrically Administered Seizure Therapy (FEAST)]. I have also conducted basic research and collaborated on health economic studies.